Having trouble viewing this email? View it in your browser.
Musella Foundation Logo and Name of Email Blast
Monday, July 22, 2024
Issue 5983
Donations

Advocacy
Alert

The time has come to rally for the Promising Pathway Act!

Click for details and to easily send letters.

Latest News

  • Webinar on LTSL-Dox plus Hyperthermia now available        

    Earlier this month, we announced a $50,000 grant to DNKO LLC for preclinical research on a treatment using heat sensitive liposomes combined with LITT for targeted drug delivery. We now have a brief webinar available on the project, as well as a donation fund set up to help get this treatment into human trials.      


  • Duke Phase 2 poliovirus trial for recurrent glioblastoma open for enrollment        

    This trial was discussed during our May Brain Tumor Awareness Month Webinar series: see here. The treatment used to be called PVSRIPO, but it's now called Lerapolturev. The trial is now recruiting, with the aim of enrolling up to 80 patients with supratentorial recurrent glioblastoma who are eligible for maximal safe resection for their recurrence. 


  • Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: a novel combinatorial immunotherapy regimen for gliomas        

    This preclinical study used an interesting combination of immunotherapies (fc-enhanced anti-ctla-4 and anti-pd-1), chemotherapy (doxorubicin), and specialized drug delivery (pulsed ultrasound and microbubbles). It was highly effective in murine models, achieving a 90% cure rate as well as immunological memory. There is a Phase 2 clinical trial at Northwestern University testing this combination in newly diagnosed glioblastoma.


  • Roon Update        

    From our friends at Roon!
    As many of you know, the Musella foundation has partnered with the Roon team to help create a wonderful online resource for those navigating glioblastoma. The app has top experts (you can see them all here https://www.roon.com/gbm/experts  from across the country answering all the questions that come up during the journey of GBM. The answers are provided via short form video and easy to consume. All the content is curated and contextualized into the journey of the disease. The newest features include AI to help you find the information you need most easily. On their home screen, you can ask the system any question you have, and it will respond with an answer sourced from the experts on Roon. From there, you can find and explore the videos.



Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details

To view past stories go to : https://virtualtrials.org/newsblast.cfm
To submit a story/press release go to: click here To unsubscribe, click here.
The article commentaries are the opinions of Al Musella, DPM and do not represent the official position of the Musella Foundation. Copyright 1992-2024 Musella Foundation - All rights reserved. No part of the Brain Tumor News Blast can be reproduced without the express written permission of the Musella Foundation.